KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like ...
Chris Paddack’s Marlins homecoming deteriorated from a disappointment to a disaster on Sunday, when the Philadelphia Phillies torched him for six runs in the first inning and coasted to a 7-2 victory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results